Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure

Horng Haur Chen, Margaret May Redfield, Lynda J. Nordstrom, Darlene P. Horton, John C Jr. Burnett

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background Brain natriuretic peptide (BNP) is a cardiac hormone with vasodilating, natriuretic, renin-angiotensin-aldosterone-inhibiting and lusitropic properties. We have demonstrated that acute subcutaneous (SQ) administration of BNP in experimental congestive heart failure results in elevation of plasma BNP and its second messenger 3′,5′-cyclic guanosine monophosphate (cGMP) with natriuresis and reduction in cardiac filling pressures. Furthermore, chronic subcutaneous BNP in experimental congestive heart failure also resulted in increases in cardiac output and decreases in pulmonary capillary wedge pressure and systemic vascular resistance. Methods The objective of the current study was to assess the safety and efficacy of repeated doses of subcutaneous human BNP, nesiritide, a recombinant form of human BNP (Scios Inc, Fremont, CA) in human subjects with New York Heart Association class II-III congestive heart failure. We defined the cardiorenal and humoral responses to subcutaneous BNP (nesiritide) administered every 12 hours with a total of 5 doses over 72 hours in a single-blind placebo-controlled design (n=8). The mean dose of nesiritide was 10 μg/kg every 12 hours. Results Initial saline placebo resulted in no change in any measured parameters (P<.05 versus baseline). With the first dose of BNP (nesiritide), cardiac output increased (4.8±0.4 to 6.4±0.5 L/min) and systolic blood pressure decreased (125±5 to 104±3 mm Hg) without a change in heart rate. Plasma BNP (167±115 to 830±470 pg/mL), cGMP (4±2 to 14±4 pmol/mL), and urinary cGMP excretion (3900±930 to 10,600±5000 pmol/min) increased with natriuresis and diuresis. Both plasma renin activity and plasma aldosterone decreased. These favorable biologic responses were observed with the fifth dose 72 hours after the initial dose. All the subjects tolerated the study well without any adverse events except for 1 subject who had a vasovagal episode during micturition after receiving the fifth dose on day 3. Conclusion We conclude that subcutaneous administration of BNP (nesiritide) represents a novel and efficacious therapeutic strategy in human congestive heart failure to deliver BNP, a cardiac hormone which possesses unique cardiorenal and neurohumoral properties.

Original languageEnglish (US)
Pages (from-to)115-119
Number of pages5
JournalJournal of Cardiac Failure
Volume10
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Hormones
Cyclic GMP
Natriuresis
Aldosterone
Renin
Cardiac Output
Placebos
Blood Pressure
Guanosine Monophosphate
Pulmonary Wedge Pressure
Urination
Diuresis
Angiotensins
Second Messenger Systems
Vascular Resistance

Keywords

  • cGMP
  • kidney
  • Natriuretic peptides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. / Chen, Horng Haur; Redfield, Margaret May; Nordstrom, Lynda J.; Horton, Darlene P.; Burnett, John C Jr.

In: Journal of Cardiac Failure, Vol. 10, No. 2, 04.2004, p. 115-119.

Research output: Contribution to journalArticle

@article{7539cd7d5baa45d4a635fe93cdf68af1,
title = "Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure",
abstract = "Background Brain natriuretic peptide (BNP) is a cardiac hormone with vasodilating, natriuretic, renin-angiotensin-aldosterone-inhibiting and lusitropic properties. We have demonstrated that acute subcutaneous (SQ) administration of BNP in experimental congestive heart failure results in elevation of plasma BNP and its second messenger 3′,5′-cyclic guanosine monophosphate (cGMP) with natriuresis and reduction in cardiac filling pressures. Furthermore, chronic subcutaneous BNP in experimental congestive heart failure also resulted in increases in cardiac output and decreases in pulmonary capillary wedge pressure and systemic vascular resistance. Methods The objective of the current study was to assess the safety and efficacy of repeated doses of subcutaneous human BNP, nesiritide, a recombinant form of human BNP (Scios Inc, Fremont, CA) in human subjects with New York Heart Association class II-III congestive heart failure. We defined the cardiorenal and humoral responses to subcutaneous BNP (nesiritide) administered every 12 hours with a total of 5 doses over 72 hours in a single-blind placebo-controlled design (n=8). The mean dose of nesiritide was 10 μg/kg every 12 hours. Results Initial saline placebo resulted in no change in any measured parameters (P<.05 versus baseline). With the first dose of BNP (nesiritide), cardiac output increased (4.8±0.4 to 6.4±0.5 L/min) and systolic blood pressure decreased (125±5 to 104±3 mm Hg) without a change in heart rate. Plasma BNP (167±115 to 830±470 pg/mL), cGMP (4±2 to 14±4 pmol/mL), and urinary cGMP excretion (3900±930 to 10,600±5000 pmol/min) increased with natriuresis and diuresis. Both plasma renin activity and plasma aldosterone decreased. These favorable biologic responses were observed with the fifth dose 72 hours after the initial dose. All the subjects tolerated the study well without any adverse events except for 1 subject who had a vasovagal episode during micturition after receiving the fifth dose on day 3. Conclusion We conclude that subcutaneous administration of BNP (nesiritide) represents a novel and efficacious therapeutic strategy in human congestive heart failure to deliver BNP, a cardiac hormone which possesses unique cardiorenal and neurohumoral properties.",
keywords = "cGMP, kidney, Natriuretic peptides",
author = "Chen, {Horng Haur} and Redfield, {Margaret May} and Nordstrom, {Lynda J.} and Horton, {Darlene P.} and Burnett, {John C Jr.}",
year = "2004",
month = "4",
doi = "10.1016/j.cardfail.2003.08.011",
language = "English (US)",
volume = "10",
pages = "115--119",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure

AU - Chen, Horng Haur

AU - Redfield, Margaret May

AU - Nordstrom, Lynda J.

AU - Horton, Darlene P.

AU - Burnett, John C Jr.

PY - 2004/4

Y1 - 2004/4

N2 - Background Brain natriuretic peptide (BNP) is a cardiac hormone with vasodilating, natriuretic, renin-angiotensin-aldosterone-inhibiting and lusitropic properties. We have demonstrated that acute subcutaneous (SQ) administration of BNP in experimental congestive heart failure results in elevation of plasma BNP and its second messenger 3′,5′-cyclic guanosine monophosphate (cGMP) with natriuresis and reduction in cardiac filling pressures. Furthermore, chronic subcutaneous BNP in experimental congestive heart failure also resulted in increases in cardiac output and decreases in pulmonary capillary wedge pressure and systemic vascular resistance. Methods The objective of the current study was to assess the safety and efficacy of repeated doses of subcutaneous human BNP, nesiritide, a recombinant form of human BNP (Scios Inc, Fremont, CA) in human subjects with New York Heart Association class II-III congestive heart failure. We defined the cardiorenal and humoral responses to subcutaneous BNP (nesiritide) administered every 12 hours with a total of 5 doses over 72 hours in a single-blind placebo-controlled design (n=8). The mean dose of nesiritide was 10 μg/kg every 12 hours. Results Initial saline placebo resulted in no change in any measured parameters (P<.05 versus baseline). With the first dose of BNP (nesiritide), cardiac output increased (4.8±0.4 to 6.4±0.5 L/min) and systolic blood pressure decreased (125±5 to 104±3 mm Hg) without a change in heart rate. Plasma BNP (167±115 to 830±470 pg/mL), cGMP (4±2 to 14±4 pmol/mL), and urinary cGMP excretion (3900±930 to 10,600±5000 pmol/min) increased with natriuresis and diuresis. Both plasma renin activity and plasma aldosterone decreased. These favorable biologic responses were observed with the fifth dose 72 hours after the initial dose. All the subjects tolerated the study well without any adverse events except for 1 subject who had a vasovagal episode during micturition after receiving the fifth dose on day 3. Conclusion We conclude that subcutaneous administration of BNP (nesiritide) represents a novel and efficacious therapeutic strategy in human congestive heart failure to deliver BNP, a cardiac hormone which possesses unique cardiorenal and neurohumoral properties.

AB - Background Brain natriuretic peptide (BNP) is a cardiac hormone with vasodilating, natriuretic, renin-angiotensin-aldosterone-inhibiting and lusitropic properties. We have demonstrated that acute subcutaneous (SQ) administration of BNP in experimental congestive heart failure results in elevation of plasma BNP and its second messenger 3′,5′-cyclic guanosine monophosphate (cGMP) with natriuresis and reduction in cardiac filling pressures. Furthermore, chronic subcutaneous BNP in experimental congestive heart failure also resulted in increases in cardiac output and decreases in pulmonary capillary wedge pressure and systemic vascular resistance. Methods The objective of the current study was to assess the safety and efficacy of repeated doses of subcutaneous human BNP, nesiritide, a recombinant form of human BNP (Scios Inc, Fremont, CA) in human subjects with New York Heart Association class II-III congestive heart failure. We defined the cardiorenal and humoral responses to subcutaneous BNP (nesiritide) administered every 12 hours with a total of 5 doses over 72 hours in a single-blind placebo-controlled design (n=8). The mean dose of nesiritide was 10 μg/kg every 12 hours. Results Initial saline placebo resulted in no change in any measured parameters (P<.05 versus baseline). With the first dose of BNP (nesiritide), cardiac output increased (4.8±0.4 to 6.4±0.5 L/min) and systolic blood pressure decreased (125±5 to 104±3 mm Hg) without a change in heart rate. Plasma BNP (167±115 to 830±470 pg/mL), cGMP (4±2 to 14±4 pmol/mL), and urinary cGMP excretion (3900±930 to 10,600±5000 pmol/min) increased with natriuresis and diuresis. Both plasma renin activity and plasma aldosterone decreased. These favorable biologic responses were observed with the fifth dose 72 hours after the initial dose. All the subjects tolerated the study well without any adverse events except for 1 subject who had a vasovagal episode during micturition after receiving the fifth dose on day 3. Conclusion We conclude that subcutaneous administration of BNP (nesiritide) represents a novel and efficacious therapeutic strategy in human congestive heart failure to deliver BNP, a cardiac hormone which possesses unique cardiorenal and neurohumoral properties.

KW - cGMP

KW - kidney

KW - Natriuretic peptides

UR - http://www.scopus.com/inward/record.url?scp=3042754038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042754038&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2003.08.011

DO - 10.1016/j.cardfail.2003.08.011

M3 - Article

C2 - 15101022

AN - SCOPUS:3042754038

VL - 10

SP - 115

EP - 119

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 2

ER -